COVID-19 (Coronavirus) Update

A Phase 1 Open-label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients with Advanced B-cell Malignancies

Protocol No
Principal Investigator
Nirav Shah
STRO-001 belongs to a class of drugs known as antibody drug conjugates (ADC). An antibody is a protein that is produced by the immune system to identify and get rid of foreign objects like bacteria. ADCs are composed of an antibody attached to an anticancer drug. The antibody portion of an ADC is designed to target cancer cells by binding to specific proteins on the cancer cell surface. Once attached to the cell, the ADC is taken inside the tumor cell and the anticancer drug is released inside to kill the cancer cell. STRO-001 is an ADC that binds to a protein known as Cluster of Differentiation 74 (CD74). CD74 is a surface protein that is overexpressed (making too many copies of a particular protein) on certain cancer cells. CD74 has been observed in about 90% of cancers like yours (B-cellmalignancies) that have been tested. In this study, STRO-001 is planned for use in subjects with relapsed /refractory B-cell malignancies, MM and NHL including subtypes diffuse large B cell lymphoma (DLBCL), indolent (low-grade) lymphomas such as follicular lymphoma (FL) and mantle cell lymphoma (MCL) who have progressed after currently available therapies.
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Participating Institutions
Froedtert Hospital
Share This: